Filter by
Format
All
Sort by
Newest

Metabolic

  • Empagliflozin
  • Linagliptin
/my/metabolic/empagliflozin/heart-failure-got-treatment/early-benefits

HFGT||Early Benefits
/my/metabolic/empagliflozin/heart-failure-got-treatment/cardiac-remodeling

HFGT||Cardiac Remodeling
/my/metabolic/empagliflozin/heart-failure-got-treatment/what-doctors-experience-jardiance-safety-profile

2:45
HFGT||What is doctor’s experience on Jardiance safety profile?
/my/metabolic/empagliflozin/heart-failure-got-treatment/what-benefits-would-jardiance-provide-your-patients

3:57
What benefits would Jardiance provide to your patients?
/my/metabolic/empagliflozin/heart-failure-got-treatment/how-does-jardiance-simplify-hf-treatment

3:01
How does Jardiance simplify HF treatment?
/my/metabolic/empagliflozin/lets-talk/what-are-kidney-benefits-empagliflozin-can-offer-heart-failure-patients

3:01

PTPHF||What are the kidney benefits that empagliflozin can offer to heart failure patients?
/my/metabolic/empagliflozin/lets-talk/what-makes-sglt2i-ideal-hf-therapy

3:54

PTPHF||What makes SGLT2i an ideal HF therapy?
/my/metabolic/empagliflozin/lets-talk/what-role-empagliflozin-patients-hospitalized-heart-failure

4:28

PTPHF||What is the role of empagliflozin in patients hospitalized for heart failure?
/my/metabolic/empagliflozin/lets-talk/what-do-we-know-about-consistency-results-empagliflozin-across-spectrum-ejection

2:52

PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?
/my/metabolic/empagliflozin/lets-talk/what-impact-treatment-landscape-early-benefits-seen-emperor-trials

2:27
PTPHF||What is the impact on the treatment landscape from the early benefits seen in the EMPEROR trials?
/my/metabolic/empagliflozin/lets-talk/what-impact-sglt-2i-trials-hfpef

5:42

PTPHF||What is the impact of SGLT-2i trials in HFpEF?
/my/metabolic/empagliflozin/lets-talk/how-has-hfpef-guidelines-evolved-advent-sglt2i-trials

4:22

PTPHF||How has the HFpEF guidelines evolved with the advent of SGLT2i trials?
/my/metabolic/empagliflozin/lets-talk/guidelines-recommend-4-pillar-approach-managing-hfref-what-practical-approach

4:25

PTPHF||Guidelines recommend the 4-pillar approach in managing HFrEF. What is a practical approach to implement this?
/my/metabolic/empagliflozin/heart-failure-got-treatment/are-benefits-jardiance-similar-both-hfref-and-hfpef-treatment

2:15

Are the Benefits of Jardiance similar in both HFrEF and HFpEF treatment?
/my/metabolic/empagliflozin/heart-failure-got-treatment/hfgt-what-value-jardiance-hf-treatment

3:44

What is the value of Jardiance in HF treatment?
/my/metabolic/empagliflozin/heart-failure-got-treatment/what-value-jardiance-hf-treatment

3:30
How does Jardiance change the way physician treat HF?
/my/metabolic/empagliflozin/heart-failure-got-treatment/how-do-you-recognise-hf-patient

3:45

How do you recognise a HF patient?
/my/metabolic/empagliflozin/heart-failure-got-treatment/what-biggest-unmet-need-hf-treatment

3:07
What is the Biggest Unmet Need in HF Treatment?
/my/metabolic/empagliflozin/heart-failure-got-treatment/what-do-you-look-forward-most-latest-indication-jardiance

4:04
What do you look forward the most with the latest indication of Jardiance?
/my/metabolic/empagliflozin/2022-ice-aoce-afes-bi-symposium

ICE2022||2022 ICE/AFES/AOCE Congress - BI Symposium
/my/metabolic/empagliflozin/prescribing-information/jardiance-prescribing-information

Jardiance® Prescribing Information
/my/metabolic/empagliflozin/prescribing-information/jardiance-duo-prescribing-information

Jardiance Duo® Prescribing Information
/my/metabolic/linagliptin/carmelina/robust-cvot-program-carmelina

1:52
Robust CVOT program - CARMELINA
/my/metabolic/linagliptin/carmelina/robust-cvot-program-carolina

2:03
Robust CVOT program - CAROLINA
/my/metabolic/linagliptin/simplicity/advances-linagliptin-has-brought-t2d-care

3:56
Advances That Linagliptin Has Brought to T2D Care
/my/metabolic/linagliptin/carmelina/spotlight-carmelina

2:22
Spotlight on CARMELINA
/my/metabolic/linagliptin/efficacy/spotlight-efficacy-data

1:26
Spotlight on efficacy data
/my/metabolic/linagliptin/efficacy/spotlight-efficacy-broad-range-patients

4:16
Spotlight on efficacy in a broad range of patients
/my/metabolic/linagliptin/simplicity/linagliptin-helps-simplify-management-t2d

1:29
Linagliptin helps simplify the management of T2D
/my/metabolic/linagliptin/simplicity/defining-simplicity-clinical-practice

6:06
Defining Simplicity in Clinical Practice
/my/metabolic/linagliptin/carmelina/spotlight-carolina

2:33
Spotlight on CAROLINA
/my/metabolic/linagliptin/convenience/carmelina-and-carolina-extensive-dataset-unique-cvot-programme

0:36
CARMELINA and CAROLINA: An extensive dataset from a unique CVOT programme.
/my/metabolic/linagliptin/carmelina/spotlight-carmelina-adverse-events

0:53
Spotlight on CARMELINA adverse events
/my/metabolic/linagliptin/convenience/spotlight-safety-data

0:24
Spotlight on safety data
/my/metabolic/linagliptin/simplicity/10-years-simplicity-trajenta

1:59
10 years of Simplicity with Trajenta
/my/metabolic/linagliptin/carmelina/trajenta-carmelina-carolina-elderly-infographic

Trajenta Elderly CVOT
/my/metabolic/linagliptin/carmelina/carmelina-trial-2020

00:00
CARMELINA Trial 2020
/my/metabolic/linagliptin/prescribing-information/trajenta-duo-prescribing-information

Linagliptin + Metformin HCl (Trajenta Duo®) Prescribing Information
/my/metabolic/linagliptin/prescribing-information/trajenta-prescribing-information

Linagliptin (Trajenta®) Prescribing Information

Cardiovascular

  • Dabigatran etexilate
  • Telmisartan
/my/cardiovascular/dabigatran-etexilate/patient-materials/video-af-what-why-how

4:04
Video AF: What? Why? How?
/my/cardiovascular/dabigatran-etexilate/patient-materials/patient-hcp-dialogue-tool

Patient-HCP Dialogue Tool
/my/cardiovascular/dabigatran-etexilate/patient-materials/patient-alert-card

Patient Alert Card
/my/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-praxbind

Prescribing Information for Praxbind®
/my/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-pradaxa

Prescribing Information for Pradaxa®
/my/cardiovascular/telmisartan/video/delta-lock-structure

1:24
Delta Lock Structure
/my/cardiovascular/telmisartan/video/cv-protection-benefits

0:58
CV Protection Benefits
/my/cardiovascular/telmisartan/video/what-edge-telmisartan-over-other-arbs-terms-anti-inflammatory-effects-diabetic-patients

0:49
What is the edge of Telmisartan over other ARBs in terms of anti-inflammatory effects for diabetic patients?

Oncology

  • Afatinib
/my/oncology/giotrif/sequencing/real-world-effectiveness-sequential-giotrif-osimertinib-toast-publication

3:57
RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - TOAST Publication
/my/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-vs-osimertinib-data-japan

3:01
RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan
/my/oncology/giotrif/sequencing/rwdri-real-world-effectiveness-sequential-giotrif-osimertinib-data-giotag-and-reset-studies

2:20
RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies
/my/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-brain-metastases-data-korea-and-taiwan

2:37
RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan
/my/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-gioswing-sequential-cohort-combined-analysis

SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
/my/oncology/giotrif/sequencing/totality-outcome-of-afatinib-giotrif-sequential-treatment-in-patients-with-egfrm-nsclc

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC
/my/oncology/giotrif/efficacy/south-korean-dataset-frontline-giotrif-uncommon-egfr-mutations

MYBIONEGIO2022||South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
/my/oncology/giotrif/expert-conversations/eee-online-modules/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-qa

00:00
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)
/my/oncology/giotrif/expert-conversations/eee-online-modules/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-lecture

00:00
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
/my/oncology/giotrif/sequencing/totality-outcome-afatinib-giotrif-sequential-treatment-patients-egfrm-nsclc

Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort)
/my/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-upswing-sequential-cohort

GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
/my/oncology/giotrif/efficacy/giotrif-safety-and-effectiveness-real-world

GIOTRIF® safety and effectiveness in the real world
/my/oncology/giotrif/efficacy/real-world-evidence-giotrif-japan

Real-world evidence: GIOTRIF® in Japan
/my/oncology/giotrif/expert-conversations/eee-online-modules/uncovering-uncommon-efficacy-afatinib-uncommon-and-compound-mutations

00:00
Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations
/my/oncology/giotrif/efficacy/real-world-evidence-giotrif-taiwan

MYSEREAL||Real-world evidence: GIOTRIF® in Taiwan
/my/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-south-korea-reset-study

MYSEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study
/my/oncology/giotrif/expert-conversations/eee-online-modules/personalized-approach-lung-adenocarcinoma-egfr-tki-therapy-prolong

15:40
MYEEE||PeRsonalized apprOach in Lung adenocarciNoma with EGFR-TKI therapy (PROLONG)
/my/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite-dose-modification

MYGIO2022COM||GIOTRIF® maintains efficacy despite dose modification
/my/oncology/giotrif/expert-conversations/closing-gap-advanced-aquamous-cell-lung-cancer-managementqa

18:34
Closing the gap in: ADVANCED AQUAMOUS CELL LUNG CANCER MANAGEMENT(Q&A)
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/patient-case-afatinib-patients-squamous-cell-carcinoma-lung

12:29
Patient Case: AFATINIB IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE LUNG
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/squamous-nsclc-where-do-targeted-therapies-fit

23:51
Squamous NSCLC: WHERE DO TARGETED THERAPIES FIT IN?
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/first-line-treatment-strategies-egfrm-nsclc-osimertinib-upfront-approach

13:45

First Line Treatment Strategies in EGFRm NSCLC: Osimertinib in the Upfront Approach
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/new-perspectives-diagnostic-testing-lung-cancer

29:21

New Perspectives in Diagnostic Testing in Lung Cancer
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/year-review-therapeutic-advances-treatment-advanced-nsclc

33:03

The Year in Review : Therapeutic Advances in the Treatment of of Advanced NSCLC
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/first-line-treatment-strategies-egfrm-nsclc-egfr-tkis-based-combination-treatment

22:35

First Line Treatment Strategies in EGFRm NSCLC: EGFR TKIs-based Combination Treatment
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/therapeutic-advances-other-targetable-oncogenic-driver-mutations-nsclc

26:34

Therapeutic Advances in Other Targetable Oncogenic Driver Mutations in NSCLC
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/after-egfr-tkis-management-advanced-nsclc-following-progression-egfr-tkis

30:04

After the EGFR TKIs: Management of Advanced NSCLC Following Progression on EGFR TKIs
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/new-reatment-paradigms-early-stage-egfr-mutant-nsclc

29:47

New reatment Paradigms in Early-Stage EGFR Mutant NSCLC
/my/oncology/giotrif/expert-conversations/inspire-updates-lung-cancer/the-evolving-landsacpe-of-immuno-oncology-in-nslc

32:38
The Evolving Landsacpe of Immuno-Oncology in NSCLC
/my/oncology/giotrif/efficacy/video-uncommon-egfr-pooled-analysis-693-patients

2:41
Video: Uncommon EGFR pooled analysis in 693 patients
/my/oncology/giotrif/efficacy/giotrif-treatment-nsclc-harbouring-uncommon-egfr-mutations-published-pooled-analysis-693

SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients
/my/oncology/giotrif/efficacy/giotrif-real-world-data-patientss-cns-involvement

SEREAL||GIOTRIF® RWE in patients with brain metastases
/my/oncology/giotrif/efficacy/giotrif-delays-median-time-cns-progression-versus-chemotherapy

SEREAL||Impact of GIOTRIF® in delaying CNS progression
/my/oncology/giotrif/efficacy/taiwan-real-world-data

SEREAL||GIOTRIF® RWE in Taiwan
/my/oncology/giotrif/dosing-and-administration/management-giotrif-adverse-events-real-world

SEREAL||Management of GIOTRIF® adverse events in the real world
/my/oncology/giotrif/efficacy/consistent-efficacy-giotri-observed-across-real-world-studies

SEREAL||GIOTRIF® efficacy in the real-world
/my/oncology/giotrif/dosing-and-administration/results-realgido-global-real-world-study

SEREAL||RealGiDo: Impact of GIOTRIF® dose adjustment in the real-world setting
/my/oncology/giotrif/sequencing/japan-real-world-evidence-supports-sequential-treatment-use-upfront-2nd-generation-tki

SEREAL||GIOTRIF® sequential RWE in Japan
/my/oncology/giotrif/sequencing/giotag-1st-global-study-show-feasibility-sequential-therapy-giotrif-followed-osimertinib

SEREAL||GioTag sequence may delay time to chemotherapy
/my/oncology/giotrif/sequencing/post-hoc-analyses-lux-lung-trials-giotrifr-followed-3rd-generation-tki

SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Impact on OS)
/my/oncology/giotrif/sequencing/uptake-subsequent-therapy-lux-lung-3-6-and-7

SEREAL||GIOTRIF® followed by 3rd generation TKI in the LUX-Lung trials (Uptake rate)
/my/oncology/giotrif/efficacy/giotrif-significantly-reduces-relative-risk-disease-progression-or-death-vs-gefitinib

SEREAL||GIOTRIF® in LUX-Lung 7
/my/oncology/giotrif/efficacy/first-line-giotrif-data-over-30-real-world-studies-date

SEREAL||GIOTRIF® real world experience in Asia
/my/oncology/giotrif/expert-conversations/treatment-stratergy-EGFR

00:00
Malaysia Region Treatment stratergy with EGFR-TKIs Asian setting
/my/oncology/giotrif/expert-conversations/tumour-heterogenity

00:00
Malaysia Region Tumour Heterogeneity in Lung Cancer Asian setting
/my/oncology/giotrif/expert-conversations/Biomarker-Detection-Part1

00:00
Malaysia Region Biomarker Detection in Lung Cancer The Pros and Cons of Multiplex Testing Part 1
/my/oncology/giotrif/expert-conversations/Biomarker-Detection-Part2

00:00
Malaysia Region Biomarker Detection in Lung Cancer The Pros and Cons of Multiplex Testing Part 2
/my/oncology/giotrif/expert-conversations/Biomarker-Detection-Part3

00:00
Malaysia Region Biomarker Detection in Lung Cancer The Pros and Cons of Multiplex Testing Part 3
/my/oncology/giotrif/expert-conversations/Resistance-Mechanisms-Part1

00:00
Malaysia Region Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSLC Part 1
/my/oncology/giotrif/expert-conversations/Resistance-Mechanisms-Part2

00:00
Malaysia Region Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSLC Part 2
/my/oncology/giotrif/expert-conversations/Resistance-Mechanisms-Part3

00:00
Malaysia Region Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSLC Part 3
/my/oncology/giotrif/expert-conversations/Clinical-Research-Part1

00:00
Malaysia Region Latest advancement in Lung Cancer Clinical Research Part 1
/my/oncology/giotrif/expert-conversations/Clinical-Research-Part2

00:00
Malaysia Region Latest advancement in Lung Cancer Clinical Research Part 2
/my/oncology/giotrif/expert-conversations/Clinical-Research-Part3

00:00
Malaysia Region Latest advancement in Lung Cancer Clinical Research Part 3
/my/oncology/giotrif/expert-conversations/advanced-NSCLC-Part1

00:00
Malaysia Region Latest advances in treating advanced NSCLC with driver mutations Part 1
/my/oncology/giotrif/expert-conversations/advanced-NSCLC-Part2

00:00
Malaysia Region Latest advances in treating advanced NSCLC with driver mutations Part 2
/my/oncology/giotrif/expert-conversations/advanced-NSCLC-Part3

00:00
Malaysia Region Latest advances in treating advanced NSCLC with driver mutations Part 3
/my/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive

Publication: GioTag Final Analysis
/my/oncology/giotrif/efficacy/giotrif-delays-onset-risk-cns-progression

GIOTRIF® delays onset and risk of CNS progression in patients with or without brain metastases
/my/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc

MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC
/my/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response

MYGIO2022COM||GIOTRIF® provides ≥3 years long-term response even with dose modification
/my/oncology/giotrif/safety/xerosis-management

AE management in focus: Xerosis
/my/oncology/giotrif/safety/stomatitis-management

AE management in focus: Stomatitis
/my/oncology/giotrif/safety/scalp-lesion-management

AE management in focus: Scalp lesion
/my/oncology/giotrif/safety/strategies-optimise-management-egfr-tki-related-side-effects

Strategies to optimise the management of EGFR  TKI-related side effects
/my/oncology/giotrif/efficacy/giotrif-efficacy-and-safety-elderly

Giotrif® efficacy and safety in elderly EGFRm+ NSCLC patients
/my/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif

Pre-clinical and clinical activity of GIOTRIF® in uncommon EGFR mutations
/my/oncology/giotrif/safety/ae-management-focus-diarrhoea

AE management in focus: Diarrhoea
/my/oncology/giotrif/safety/ae-management-focus-paronychia

AE management in focus: Paronychia
/my/oncology/giotrif/safety/ae-management-focus-skin-rash

AE management in focus: Skin Rash
/my/oncology/giotrif/sequencing/sequential-treatment-afatinib

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell-lung cancer: an observational study
/my/oncology/giotrif/prescribing-information

Afatinib (Giotrif®) Prescribing Information

Respiratory

  • Tiotropium + Olodaterol
/my/respiratory/spiolto/respimat/boehringer-ingelheim-smi-vs-dpi

Boehringer Ingelheim - SMI Vs DPI
/my/respiratory/spiolto/respimat/respimat-delivers-drug-actively

03:29
Respimat delivers drug actively without the need of COPD patients to forcefully inhale
/my/respiratory/spiolto/guidelines/gold-2019-role-lama-laba

01:49
GOLD 2019 - Role of LAMA/LABA
/my/respiratory/spiolto/guidelines/gold-update-2019

08:30
GOLD Update 2019
/my/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme

TOVITO® Clinical Trial Programme
/my/respiratory/spiolto/respimat/importance-particle-size

01:17
Respimat® produces a soft mist of high fine particle fraction aerosol which delivers Spiolto® deep into patients' lungs
/my/respiratory/spiolto/respimat/how-assemble

01:23
Respimat® Device Assembly - Preparation for First Use
/my/respiratory/spiolto/respimat/how-use

00:51
Preparing Respimat® for Daily Use
/my/respiratory/spiolto/efficacy/treatment-lamalaba-vs-lamalabaics

02:02
WISDOM trial suggests only a minority of COPD patients benefit from the addition of an ICS on top of SPIRIVA+LABA, and these are clearly identifiable
/my/respiratory/spiolto/efficacy/treatment-lamalaba-vs-labaics

01:35
ENERGITO and FLAME demonstrate consistent superiority with LAMA/LABA vs LABA/ICS for all outcomes related to lung function, symptom control and exacerbations
/my/respiratory/spiolto/efficacy/early-intervention-optimize-lung-function

02:13
Early intervention to optimize lung function
/my/respiratory/spiolto/prescribing-information

Spiolto® Respimat® Prescribing Information

Inflammation

  • Nintedanib
/my/inflammation/nintedanib/about-pulmonary-fibrosis/identifying-ild-patients-ra-dr-anna-hoffman-vold

4:17

A1-R101||A2-R101||Identifying ILD in patients with RA by Dr. Anna Hoffman-Vold
/my/inflammation/nintedanib/about-pulmonary-fibrosis/how-identify-patients-ra-ild-who-can-benefit-ofev

A1-R101||A2-R101||How to identify patients with RA-ILD who can benefit from OFEV
/my/inflammation/nintedanib/about-pulmonary-fibrosis/ra-ild-delphi-consensus-screening-algorithm

A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM
/my/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-ppf-diagnosis-and-treatment-atsersjrsalat-guideline

FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline
/my/inflammation/nintedanib/expert-view/side-effect-management-adherence-panel-discussion-dr-nicole-goh-ms-charlotte-ild-nurse

28:58
FSIN||Side effect management & adherence (Panel discussion) - by Dr Nicole Goh, Ms Charlotte (ILD Nurse), Dr Felix, Dr Voon
/my/inflammation/nintedanib/expert-view/recent-developments-management-ild-dr-felix-chua-royal-brompton-hospital

24:26
FSIN||Recent developments in the management of ILD - Dr Felix Chua (Royal Brompton Hospital)
/my/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-ild-ppf-patients-ctd

FSIN||How to recognize ILD in PPF patients with CTD
/my/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-focus-autoimmune-ilds

Progressive Pulmonary Fibrosis: focus on autoimmune ILDs
/my/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-diagnosis-treatment-atsersjrsalat-guideline

Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline
/my/inflammation/nintedanib/about-pulmonary-fibrosis/importance-prompt-treatment-ipf

The Importance of Prompt Treatment of IPF
/my/inflammation/nintedanib/mechanism-action/experts-video-ild-management

1:36

A2-R101||Experts Video on ILD Management
/my/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-oliver-distler

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. Oliver Distler
/my/inflammation/nintedanib/expert-view/ppf-guideline-prof-toby-maher

1:28
A1-R101||A2-R101||PPF Guideline - Prof Toby Maher
/my/inflammation/nintedanib/expert-view/early-use-anti-fibrotics-and-benefits-patients-prof-luca-richeldi-prof-toby-maher

0:59
Early use of Anti-Fibrotics and the benefits to patients (Prof. Luca Richeldi & Prof. Toby Maher)
/my/inflammation/nintedanib/expert-view/expert-videos-ssc-ild-management-chapter-2

3:58
A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 2
/my/inflammation/nintedanib/expert-view/expert-videos-ssc-ild-management-chapter-5

2:34

A1-R101||A2-R101||Expert Videos on SSc-ILD Management - Chapter 5
/my/inflammation/nintedanib/mechanism-action/ctd-ild-pathophysiology-moa

4:39

A1-R101||CTD-ILD Pathophysiology & MoA
/my/inflammation/nintedanib/about-pulmonary-fibrosis/ra-ild-patient-profile-julie

A1-R101||A2-R101||RA-ILD Patient Profile - Julie
/my/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-m-aringer

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. M. Aringer
/my/inflammation/nintedanib/expert-view/rheum-mte-management-strategies-key-highlights-dr-anna-maria-hoffmann-vold

A2-R101||Rheum MTE – Management Strategies Key highlights -Dr. Anna Maria Hoffmann-Vold
/my/inflammation/nintedanib/about-pulmonary-fibrosis/ssc-ild-patient-profile-stephanie

A1-R101||A2-R101||SSc-ILD Patient Profile - Stephanie
/my/inflammation/nintedanib/expert-view/importance-early-ssc-ild-diagnosis

4:16
Expert Videos on SSc-ILD Management - Chapter 1
/my/inflammation/nintedanib/expert-view/meet-expert-dr-hoffmann-vold-key-summary-video

5:20

A2-R101||Meet-the-Expert with Dr. Hoffmann-Vold: Key Summary Video
/my/inflammation/nintedanib/expert-view/meet-expert-dr-oliver-distler-key-summary-video

8:36
Meet-the-Expert with Dr. Oliver Distler: Key Summary Video
/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-droliver-distler

Meet-the-Expert with Dr. Oliver Distler: Highlights Report
/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-dramhoffmann-vold

Meet-the-Expert with Dr. Hoffmann-Vold: Highlights Report
/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drvsmith

Meet-the-Expert with Dr. Vanessa Smith: Highlights Report
/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drmaringer

Meet-the-Expert with Dr. Martin Aringer: Highlights Report
/my/inflammation/nintedanib/expert-view/prof-martin-kolb-why-early-detection-and-intervention-important-ild

2:19
With Prof Martin Kolb: Why is early detection and intervention important in ILD?
/my/inflammation/nintedanib/management-sarcoidosis

27:30
Management of Sarcoidosis
/my/inflammation/nintedanib/expert-view/3rd-indication-approval-ofev-paradigm-shift-treatment-pf-ild-qa

13:05
3rd Indication Approval for OFEV® - A Paradigm Shift in the Treatment of PF-ILD (Q&A)
/my/inflammation/nintedanib/expert-view/3rd-indication-approval-ofev-paradigm-shift-treatment-pf-ild-lecture

1:49:27
3rd Indication Approval for OFEV® - A Paradigm Shift in the Treatment of PF-ILD (Lecture)
/my/inflammation/nintedanib/efficacy/3rd-indication-approval-ofev-paradigm-shift-treatment-pf-ild

2:30
3rd Indication Approval for OFEV® - A Paradigm Shift in the Treatment of PF-ILD
/my/inflammation/nintedanib/safety/listen-our-experts-summarise-safety-profile-ofev-inbuild

2:10
INBUILD® Trial Safety
/my/inflammation/nintedanib/efficacy/ofev-reduces-risk-acute-exacerbations-seen-inbuild

3:10
INBUILD® Trial Efficacy (Acute Exacerbations)
/my/inflammation/nintedanib/efficacy/ofev-first-and-only-approved-therapy-pf-ild

2:01
INBUILD® Trial Efficacy (FVC)
/my/inflammation/nintedanib/efficacy/listen-our-experts-share-their-insights-why-inbuild-important-study-patients-pf-ild

2:34
INBUILD® Trial Introduction
/my/inflammation/nintedanib/about-pulmonary-fibrosis/discover-common-link-interstitial-lung-diseases

3:06

Pathophysiology of Pulmonary Fibrosis in ILD
/my/inflammation/nintedanib/about-pulmonary-fibrosis/listen-to-our-experts-explain-the-importance-of-proactive-monitoring-in-patients-with-ild

2:04
Monitoring for Progression
/my/inflammation/nintedanib/about-pulmonary-fibrosis/listen-our-experts-share-their-thoughts-what-pf-ild-and-high-unmet-need-surrounding

2:29
Progressive Fibrosing ILD
/my/inflammation/nintedanib/prescribing-information/nintedanib-ofev-prescribing-information

Nintedanib (Ofev®) Prescribing Information
/my/inflammation/nintedanib/dosage/offer-your-patients-one-capsule-twice-daily

Dosing simplicity with OFEV®
/my/inflammation/nintedanib/mechanism-action/ofev-inhibits-fundamental-pathways-fibrosis

2:48
MYOFV2022COM||OFEV® MOA in SSc-ILD
/my/inflammation/nintedanib/mechanism-action/approved-anti-fibrotic-known-and-established-mechanism

3:23
OFEV® MOA in IPF
/my/inflammation/nintedanib/safety/most-common-gi-related-adverse-events-ofev-are-mild-moderate

MYOFV2022COM||Managing your SSc-ILD patients on OFEV®
/my/inflammation/nintedanib/safety/management-ofev-related-diarrhoea

Managing your IPF patients on OFEV®
/my/inflammation/nintedanib/expert-view/learn-experts-why-it-important-reduce-ae-ipf

2:05
Interpreting acute exacerbations data with Prof. Luca Richeldi and Prof. Toby Maher
/my/inflammation/nintedanib/efficacy/largest-prospective-phase-iii-clinical-trial-patients-ssc-ild

MYOFV2022COM||SENSCIS® trial
/my/inflammation/nintedanib/efficacy/consistent-treatment-effect-ofev-irrespective-disease-stage

OFEV® across different disease severities
/my/inflammation/nintedanib/efficacy/ofev-slows-fvc-decline-regardless-baseline-fvc-impairment

OFEV® in IPF patients with FVC ≤50% predicted
/my/inflammation/nintedanib/efficacy/exploratory-analysis-suggests-ofev-may-extend-life-expectancy

Mortality data in IPF
/my/inflammation/nintedanib/efficacy/ofev-significantly-reduces-risk-ae-ipf-pooled-inpulsis-1-and-2

OFEV® and acute IPF exacerbations
/my/inflammation/nintedanib/about-pulmonary-fibrosis/vigilance-and-proactivity-are-critical-reducing

MYOFV2022COM||Screening for ILD in your SSc patients
/my/inflammation/nintedanib/about-pulmonary-fibrosis/regular-screening-critical-ild-can-develop-early

MYOFV2022COM||ILD is the leading cause of mortality in SSc
/my/inflammation/nintedanib/about-pulmonary-fibrosis/once-lung-function-lost-ipf-it-lost-forever

Lung function decline
/my/inflammation/nintedanib/about-pulmonary-fibrosis/learn-how-acute-exacerbation-ipf-can-impact

Risk of acute exacerbations